

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2016 November 14; 22(42): 9251-9450



**EDITORIAL**

- 9251 Hepatic encephalopathy: Ever closer to its big bang

*Souto PA, Marcotegui AR, Orbea L, Skerl J, Perazzo JC*

**FRONTIER**

- 9257 Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis

*Czaja AJ*

**DIAGNOSTIC ADVANCES**

- 9279 Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update

*Cong WM, Bu H, Chen J, Dong H, Zhu YY, Feng LH, Chen J; Guideline Committee*

**REVIEW**

- 9288 Glycoproteins and glycoproteomics in pancreatic cancer

*Pan S, Brentnall TA, Chen R*

- 9300 Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases

*Billmeier U, Dieterich W, Neurath MF, Atreya R*

- 9314 Acute kidney injury and post-reperfusion syndrome in liver transplantation

*Umbro I, Tinti F, Scalera I, Evison F, Gunson B, Sharif A, Ferguson J, Muiesan P, Mitterhofer AP*

**MINIREVIEWS**

- 9324 Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes?

*Mohammed N, Subramanian V*

**ORIGINAL ARTICLE****Basic Study**

- 9333 Carbon monoxide contributes to the constipating effects of granisetron in rat colon

*Nacci C, Fanelli M, Potenza MA, Leo V, Montagnani M, De Salvia MA*

- 9346 Genetic polymorphism in *CD14* gene, a co-receptor of TLR4 associated with non-alcoholic fatty liver disease

*Kapil S, Duseja A, Sharma BK, Singla B, Chakraborti A, Das A, Ray P, Dhiman RK, Chawla Y*

- 9356 Increased CD4<sup>+</sup>CD45RA<sup>+</sup>FoxP3<sup>low</sup> cells alter the balance between Treg and Th17 cells in colitis mice  
*Ma YH, Zhang J, Chen X, Xie YF, Pang YH, Liu XJ*

- 9368 IRF5 regulates lung macrophages M2 polarization during severe acute pancreatitis *in vitro*  
*Sun K, He SB, Qu JG, Dang SC, Chen JX, Gong AH, Xie R, Zhang JX*

### Retrospective Study

- 9378 Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy  
*Guion-Dusserre JF, Bertaut A, Ghiringhelli F, Vincent J, Quipourt V, Marilier S, Tharin Z, Bengrine-Lefevre L*

- 9387 Influence of night duty on endoscopic therapy for bile duct stones  
*Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Watanabe K, Nakamura J, Kikuchi H, Waragai Y, Takasumi M, Hikichi T, Ohira H*

- 9394 Irritable bowel syndrome evaluation using computed tomography colonography  
*Ohgo H, Imaeda H, Yamaoka M, Yoneno K, Hosoe N, Mizukami T, Nakamoto H*

- 9400 Lymphovascular invasion in more than one-quarter of small rectal neuroendocrine tumors  
*Kwon MJ, Kang HS, Soh JS, Lim H, Kim JH, Park CK, Park HR, Nam ES*

- 9411 Potential model for differential diagnosis between Crohn's disease and primary intestinal lymphoma  
*Zhang TY, Lin Y, Fan R, Hu SR, Cheng MM, Zhang MC, Hong LW, Zhou XL, Wang ZT, Zhong J*

- 9419 Full-thickness myotomy is associated with higher rate of postoperative gastroesophageal reflux disease  
*Wang XH, Tan YY, Zhu HY, Li CJ, Liu DL*

### Observational Study

- 9427 Occult hepatitis B virus infection is not associated with disease progression of chronic hepatitis C virus infection  
*Cho JH, Lee SS, Choi YS, Jeon YJ, Chung JW, Baeg JY, Si WK, Jang ES, Kim JW, Jeong SH*

- 9437 Prevalence of depression and anxiety in patients with chronic digestive system diseases: A multicenter epidemiological study  
*Zhang AZ, Wang QC, Huang KM, Huang JG, Zhou CH, Sun FQ, Wang SW, Wu FT*

### CASE REPORT

- 9445 Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma  
*Takano M, Kokudo T, Miyazaki Y, Kageyama Y, Takahashi A, Amikura K, Sakamoto H*

**ABOUT COVER**

Albert J Czaja, MD, Professor Emeritus of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, United States

**AIMS AND SCOPE**

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup>, and 28<sup>th</sup> each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

**INDEXING/ABSTRACTING**

*World Journal of Gastroenterology* (*WJG*) is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, Digital Object Identifier, and Directory of Open Access Journals. The 2015 edition of Journal Citation Reports® released by Thomson Reuters (ISI) cites the 2015 impact factor for *WJG* as 2.787 (5-year impact factor: 2.848), ranking *WJG* as 38 among 78 journals in gastroenterology and hepatology (quartile in category Q2).

**FLYLEAF**

**I-IX Editorial Board**

**EDITORS FOR THIS ISSUE**

**Responsible Assistant Editor:** *Xiang Li*  
**Responsible Electronic Editor:** *Fen-Fen Zhang*  
**Proofing Editor-in-Chief:** *Lian-Sheng Ma*

**Responsible Science Editor:** *Yuan Qi*  
**Proofing Editorial Office Director:** *Jin-Lei Wang*

**NAME OF JOURNAL**  
*World Journal of Gastroenterology*

**ISSN**  
ISSN 1007-9327 (print)  
ISSN 2219-2840 (online)

**LAUNCH DATE**  
October 1, 1995

**FREQUENCY**  
Weekly

**EDITORS-IN-CHIEF**  
**Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon**, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

**Stephen C Strom, PhD, Professor**, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

**Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology**, VA Long Beach Health Care System, University of California, Irvine, Irvine, CA, 5901 E. Seventh Str., Long Beach, CA 90822, United States

fornia, Irvine, CA, 5901 E. Seventh Str., Long Beach, CA 90822, United States

**EDITORIAL BOARD MEMBERS**  
All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

**EDITORIAL OFFICE**  
Jin-Lei Wang, Director  
Yuan Qi, Vice Director  
*World Journal of Gastroenterology*  
Baishideng Publishing Group Inc  
8226 Regency Drive,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>  
<http://www.wjgnet.com>

**PUBLISHER**  
Baishideng Publishing Group Inc  
8226 Regency Drive,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

**PUBLICATION DATE**  
November 14, 2016

**COPYRIGHT**  
© 2016 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

**INSTRUCTIONS TO AUTHORS**  
Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

**ONLINE SUBMISSION**  
<http://www.wjgnet.com/esps/>



## Basic Study

# Carbon monoxide contributes to the constipating effects of granisetron in rat colon

Carmela Nacci, Margherita Fanelli, Maria Assunta Potenza, Valentina Leo, Monica Montagnani, Maria Antonietta De Salvia

Carmela Nacci, Maria Assunta Potenza, Valentina Leo, Monica Montagnani, Maria Antonietta De Salvia, Department of Biomedical Sciences and Human Oncology - Pharmacology Section, Medical School, University of Bari "Aldo Moro", Piazza G. Cesare, 70124 Bari, Italy.

Margherita Fanelli, Department of Interdisciplinary Medicine, Medical School, University of Bari "Aldo Moro", Piazza G. Cesare, 70124 Bari, Italy.

**Author contributions:** Nacci C performed the majority of the experiments; Fanelli M analyzed the data; Potenza MA and Leo V participated in animal treatment; De Salvia MA designed and coordinated the research; Montagnani M and De Salvia MA wrote the paper.

**Supported by** Università degli Studi di Bari, protocol No. 10110 tit-VIII/2.

**Institutional review board statement:** The study was reviewed and approved by Università degli Studi di Bari with protocol number 10110 tit-VIII/2.

**Institutional animal care and use committee statement:** All procedures in animals were reviewed and approved by the Italian Government, Ministry of Health, with protocol number 15/12.

**Conflict-of-interest statement:** To the best of our knowledge, no conflict of interest exists.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** Maria Antonietta De Salvia, PhD, Assistant Professor, Department of Biomedical Sciences and Human Oncology - Pharmacology section, Medical School, University of Bari "Aldo Moro", Piazza G. Cesare, 70124 Bari, Italy. [mariaantonietta.desalvia@uniba.it](mailto:mariaantonietta.desalvia@uniba.it)  
Telephone: +39-80-5478425  
Fax: +39-80-5478449

**Received:** June 24, 2016

**Peer-review started:** June 29, 2016

**First decision:** August 22, 2016

**Revised:** September 16, 2016

**Accepted:** October 19, 2016

**Article in press:** October 19, 2016

**Published online:** November 14, 2016

## Abstract

### AIM

To investigate the mechanisms underlying the potential contribution of the heme oxygenase/carbon monoxide (HO/CO) pathway in the constipating effects of granisetron.

### METHODS

For *in vivo* studies, gastrointestinal motility was evaluated in male rats acutely treated with granisetron [25, 50, 75 µg/kg/subcutaneous (sc)], zinc protoporphyrin IX [ZnPPiX, 50 µg/kg/intraperitoneal (ip)] and hemin (50 µmol/L/kg/ip), alone or in combination. For *in vitro* studies, the contractile neurogenic response to electrical field stimulation (EFS, 3, 5, 10 Hz, 14 V, 1 ms, pulse trains lasting 10 s), as well as the contractile myogenic response to acetylcholine (ACh, 0.1-100 µmol/L) were evaluated on colon specimens incubated with granisetron (3 µmol/L, 15 min), ZnPPiX (10 µmol/L, 60 min) or CO-releasing molecule-3 (CORM-3, 100, 200, 400 µmol/L) alone or in combination. These experiments were performed under co-treatment with

or without atropine (3  $\mu\text{mol/L}$ , a muscarinic receptor antagonist) or N<sup>G</sup>-nitro-L-Arginine (L-NNA, 100  $\mu\text{mol/L}$ , a nitric oxide synthase inhibitor).

## RESULTS

Administration of granisetron (50, 75  $\mu\text{g/kg}$ ) *in vivo* significantly increased the time to first defecation ( $P = 0.045$  *vs* vehicle-treated rats), clearly suggesting a constipating effect of this drug. Although administration of ZnPPiX or hemin alone had no effect on this gastrointestinal motility parameter, ZnPPiX co-administered with granisetron abolished the granisetron-induced constipation. On the other hand, co-administration of hemin and granisetron did not modify the increased constipation observed under granisetron alone. When administered *in vitro*, granisetron alone (3  $\mu\text{mol/L}$ ) did not significantly modify the colon's contractile response to either EFS or ACh. Incubation with ZnPPiX alone (10  $\mu\text{mol/L}$ ) significantly reduced the colon's contractile response to EFS ( $P = 0.016$ ) but had no effect on contractile response to ACh. Co-administration of ZnPPiX and atropine (3  $\mu\text{mol/L}$ ) abolished the ZnPPiX-mediated decrease in contractile response to EFS. Conversely, incubation with CORM-3 (400  $\mu\text{mol/L}$ ) alone increased both the contractile response to EFS at 10 Hz (10 Hz:  $71.02 \pm 19.16$  *vs*  $116.25 \pm 53.70$ ,  $P = 0.01$ ) and the contractile response to ACh (100  $\mu\text{mol/L}$ ) ( $P = 0.012$ ). Co-administration of atropine abolished the CORM-3-mediated effects on the EFS-mediated response. When granisetron was co-incubated *in vitro* with ZnPPiX, the ZnPPiX-mediated decrease in colon contractile response to EFS was lost. On the other hand, co-incubation of granisetron and CORM-3 (400  $\mu\text{mol/L}$ ) further increased the colon's contractile response to EFS (at 5 Hz:  $P = 0.007$ ; at 10 Hz:  $P = 0.001$ ) and to ACh (ACh 10  $\mu\text{mol/L}$ :  $P = 0.001$ ; ACh 100  $\mu\text{mol/L}$ :  $P = 0.001$ ) elicited by CORM-3 alone. L-NNA co-administered with granisetron and CORM-3 abolished the potentiating effect of CORM-3 on granisetron on both the EFS-induced and ACh-induced contractile response.

## CONCLUSION

Taken together, findings from *in vivo* and *in vitro* studies suggest that the HO/CO pathway is involved in the constipating effects of granisetron.

**Key words:** Granisetron; Carbon monoxide; Heme oxygenase; Colon; Contraction; Neurogenic response; Myogenic response

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** We studied whether *in vivo* and *in vitro* effects of granisetron might be influenced, at least in part, by the heme oxygenase/carbon monoxide (HO/CO) pathway. Our findings demonstrate for the first time that the HO/CO pathway takes part in the contractile colon activity in rats. Interestingly, the constipating effects of granisetron are positively correlated with

levels of carbon monoxide, thus suggesting that treatments able to modulate carbon monoxide levels may potentially reduce the constipation mediated by granisetron.

Nacci C, Fanelli M, Potenza MA, Leo V, Montagnani M, De Salvia MA. Carbon monoxide contributes to the constipating effects of granisetron in rat colon. *World J Gastroenterol* 2016; 22(42): 9333-9345 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v22/i42/9333.htm> DOI: <http://dx.doi.org/10.3748/wjg.v22.i42.9333>

## INTRODUCTION

In recent decades, the role played by carbon monoxide (CO) in several biochemical processes has been increasingly recognized<sup>[1-3]</sup>. Once considered only for its lethal effects, the therapeutic use of CO has been proposed after the discovery of its potential "positive" functions (<http://clinicaltrials.gov/ct2/search>, "carbon monoxide").

CO is a gas that is produced, together with iron and biliverdin, from the catalysis of heme by the microsomal heme oxygenase (HO) enzyme. Of the two HO isoforms, HO-2 is the constitutive one, whereas HO-1 is a highly inducible isoform whose activity is intended to provide protection against oxidative stress, injury and inflammation<sup>[1,2]</sup>.

The first physiological role suggested for CO was in non-adrenergic non-cholinergic (NANC) neurotransmission at the gastrointestinal level<sup>[4]</sup>. The hypothesis of CO as a neurotransmitter is strongly supported by the wide expression of HO-2 throughout the gastrointestinal tract in the enteric nerves, as well as in the non-neuronal cells of the mucosal epithelium, smooth muscle cells, endothelium of blood vessels and interstitial cells of Cajal<sup>[3-5]</sup>. Moreover, HO-1 is upregulated in several gastrointestinal pathologies such as colitis, inflammatory bowel disease and gastric ulcers (see<sup>[3]</sup> for references). Because endogenously produced CO diffuses to blood where it binds to hemoglobin, increased HO-1 expression may result in augmented blood levels of carboxyhemoglobin (normal levels 0.8%). However, high levels of carboxyhemoglobin are more typically the consequence of smoking habits or environmental pollution<sup>[2]</sup>. Either from endogenous or exogenous sources, altered CO levels may affect physiological processes or modulate pathological conditions *via* several distinct mechanisms<sup>[6]</sup>. Ion channels have been shown to be, among others, the target of CO; thus, it is possible that CO may modulate the effects of other signals by acting directly on the same target or indirectly on the shared pool of second messengers<sup>[6-8]</sup>. A similar modulating activity of CO might also be plausible toward specific drugs; indeed, in a previous report, we observed the involvement of the

HO/CO pathway in granisetron-mediated effects on rat duodenal motility<sup>[9]</sup>.

Granisetron is a highly selective competitive antagonist of the 5-HT<sub>3</sub> receptor, the only serotonin-gated ion channel that, if activated, allows an influx of cations<sup>[10]</sup>. Granisetron is currently used for the chemotherapy-induced nausea and vomiting<sup>[11]</sup>, and constipation is reported among its side effects<sup>[12]</sup>. On the other hand, constipation is the desired effect for 5-HT<sub>3</sub> receptor antagonists such as alosetron and cilansetron in the treatment of irritable bowel syndrome with diarrhea<sup>[13]</sup> in which the delayed transit in the large bowel may reduce pain and discomfort in those patients<sup>[14]</sup>. Unfortunately, despite their clinical efficacy, the potential use of these drugs has been restricted due to reports of severe ischemic colitis (see<sup>[15]</sup> for review). Nevertheless, these observations support the ability of 5-HT<sub>3</sub> receptor antagonists to induce constipation.

To explore potential mechanisms linking the activity of the HO/CO pathway to granisetron-induced constipation, we investigated whether the constipating effects of granisetron administered *in vivo* may be modulated by agents that induce (such as hemin) or inhibit (such as zinc protoporphyrin, ZnPPiX) the endogenous HO activity. A 3 µmol/L concentration of granisetron was chosen for the present investigation based on dose-response curves previously obtained<sup>[9]</sup>. Moreover, because constipation has been ascribed to abnormalities of various contractile activities of the colon<sup>[16-19]</sup>, parallel *in vitro* studies on isolated colon preparations were performed to evaluate (1) the neurogenic contractile responses to electrical field stimulation indicative of cholinergic and non-cholinergic transmitter release from enteric neurons<sup>[20,21]</sup> in the absence and in the presence of the muscarinic antagonist atropine as well as the nitric oxide synthase inhibitor L-NNA; and (2) the myogenic contractile response to ACh, one of the major contractile neurotransmitters at the gastrointestinal level in the absence and in the presence of L-NNA.

## MATERIALS AND METHODS

### Experimental animal model

All experimental procedures were performed in accordance with the Guidelines and Authorization for the Use of Laboratory Animals (Italian Government, Ministry of Health) and according to the European Community Guidelines for Animal Care (DL 116/92, application of the European Communities Council Directive of 24 November 1986 - 86/609/EEC).

Ten-week-old male Sprague-Dawley rats weighing 220-250 g at arrival (Envigo, San Pietro al Natisone, Udine, Italy) were used. The animal protocol was designed to minimize pain or discomfort to the animals.

Rats were housed in an animal facility with monitored temperature and light (12-h cycle and 21 ± 2 °C). All cages were floored with sawdust, and bedding was replaced on a regular basis. The animals were

allowed to acclimate to the environment for at least 7 d. Rats undergoing *in vivo* treatments were randomly chosen and allocated into individual cages before initiating the study, with the remaining rats caged together (4 rats/cage) in close proximity to allow experimental animals to see and smell their companions. Rats had free access to water and food when they were not under testing. All animals were handled and trained for at least 1 wk to minimize the possible stress of the drug administration procedure.

### Gastrointestinal motility test

A repeated measures protocol was designed for *in vivo* study, so that each rat, at one-week intervals, received the following treatments either subcutaneously (sc) or intraperitoneally (ip): vehicle (1 mL/kg), granisetron (25, 50, 75 µg/kg/sc soon before testing), ZnPPiX (50 µg/kg/ip, 60 min before testing), hemin (50 µmol/L/kg/ip 24 h before testing), ZnPPiX (50 µg/kg/ip, 60 min before granisetron) with granisetron (25, 50, 75 µg/kg/sc), or hemin (50 µmol/L/kg/ip 24 h before granisetron) with granisetron (25, 50, 75 µg/kg/sc). The timing and dosing for ZnPPiX and hemin were carefully chosen to obtain the greatest level of HO inhibition or induction, respectively<sup>[9,22,23]</sup>. In a pilot study, we observed that the average time to first defecation in vehicle-treated rats was between 80-110 min (median 105 min; interquartile range 90-110; full range 80-180). Based on these preliminary findings, the observation cut-off time was set at 180 min. In the late afternoon preceding the test day, rats were fasted with free access to water. On the test day, animals were weighed and then allowed to free feed for 20 min. The amount of food eaten and the weight of the fed rats were calculated.

Following drug administration, each rat was monitored every 10 min for 180 min, and the time to first defecation was assumed as an index of whole-gut transit<sup>[24,25]</sup>.

### Tensiometric studies

After induction of general anesthesia (pentobarbital 80 mg/kg ip), rats were killed by cervical dislocation. A 3-cm section of proximal colon (1 cm from the ileocecal sphincter), obtained through a midline incision of the abdomen, was immediately placed in a cooled modified Krebs' solution (pH = 7.4) of the following composition (mmol/L): NaCl 113, KCl 4.8, MgSO<sub>4</sub> 1.2, CaCl<sub>2</sub> (H<sub>2</sub>O) 2.2, NaH<sub>2</sub>PO<sub>4</sub> 1.2, NaHCO<sub>3</sub> 25, glucose 5.5, and ascorbic acid 5.5. The specimen was then cleaned and rinsed, and a circular ring (0.5-cm length) was mounted in an organ bath (20 mL) filled with modified Krebs' solution, maintained at 37 °C and gassed with a mixture of 95% O<sub>2</sub> and 5% CO<sub>2</sub>. One end of the circular ring was connected to a metal rod, while the other end was attached to a strain gauge transducer (FORT 25, WPI, Sarasota, FL, United States). Isometric tension was measured by the PowerLab data acquisition system and recorded using Chart 5.5.5 (ADIn-

struments, Castle Hill, Australia). The colon ring was allowed to equilibrate for at least 30 min prior to the experiment. An initial load of 0.5 g tension was applied to the preparation.

The neurogenic contractile response was measured by applying a transmural stimulation (Electrical Field Stimulation, EFS) at frequencies of 3, 5, and 10 Hz (14 V, 1 ms pulse, trains lasting 10 s) through two parallel platinum electrodes connected to a stimulator (Digital Stimulator, LE 12106, Letica, Ugo Basile, Italy). The EFS results in an immediate relaxation, followed at the end of EFS by a so-called off-contraction. This contractile response is indicative of a nervous reflex that is abolished by tetrodotoxin and reduced by atropine and tachykinin antagonists<sup>[26]</sup>. Activation of enteric nerves by EFS mimics the *in vivo* conditions in which neurotransmitters are released by motor neurons to the neuroeffector apparatus; the interaction between the interstitial cells of Cajal, neurons, glial cells and smooth muscle cells generates contraction<sup>[27,28]</sup>.

The myogenic contractile response was explored by calculating the extent of contraction induced by acetylcholine (ACh, 0.1–100  $\mu\text{mol/L}$ ).

Both neurogenic and myogenic contractile responses were measured after incubation with the following agents alone or in combination: granisetron hydrochloride (3  $\mu\text{mol/L}$ , 15 min), ZnPPiX (10  $\mu\text{mol/L}$ , 60 min), L-NNA (100  $\mu\text{mol/L}$ , 20 min), and CORM-3 (100, 200, 400  $\mu\text{mol/L}$ ). For the last compound, CORM-3, a water-soluble Ru-containing compound releasing one mole of CO per mole<sup>[29]</sup>, the effect was evaluated within 10 min from administration to avoid its spontaneous breakdown.

The neurogenic contractile responses were expressed as a percentage of three consecutive contractile responses to EFS (10 Hz, 14 V, 1 ms pulse, trains lasting 10 s) recorded and averaged before drug administration.

The myogenic contractile responses to ACh (0.1–100  $\mu\text{mol/L}$ ) were expressed as a percentage of tension values elicited by the highest ACh concentration (100  $\mu\text{mol/L}$ ) before drug administration.

The activity of ZnPPiX and CORM-3 (indicative of a specific CO-dependent effect) on neurogenic contractile response was measured in the absence and in the presence of atropine (3  $\mu\text{mol/L}$ ).

### Drugs and chemicals

The following drugs were used: atropine sulphate and granisetron hydrochloride dissolved in saline (Sigma Chemical Co., St. Louis, Missouri, United States). Zinc protoporphyrin IX and hemin were dissolved in 0.1 N NaOH and equilibrated to a pH of 7.4 with HCl (Sigma Chemical Co., St. Louis, Missouri, United States). Tricarbonyl Chloro(glycinato)ruthenium (II) (CORM-3) and N<sup>G</sup>-nitro-L-Arginine (L-NNA) were dissolved in distilled water (Sigma Chemical Co., St. Louis, Missouri, United States). In *in vivo* studies, vehicle-treated rats

received the same amount of vehicle as did drug-treated animals. In *in vitro* experiments, vehicle-treated preparations were exposed to the same amount of vehicle as drug-treated preparations.

### Statistical analysis

For *in vivo* study, Friedman's ANOVA for repeated measures followed by a *post hoc* test was performed. For *in vitro* study, two-way ANOVA for repeated measures (treatment effect, frequencies or concentrations effect and interaction effect, with frequency or concentrations as repeated measure) was performed. When the interaction effect was significant, a one-way ANOVA at each frequency or concentration was performed with pre-planned multiple comparison tests for each treatment vs vehicle.

The results are presented as individual observations ( $n = 8$ ) for each *in vivo* treatment; results are expressed as the mean  $\pm$  SD of 6–8 preparations for each *in vitro* treatment. Statistical analysis was performed by the biomedical statistician Dr. Margherita Fanelli (coauthor) using SPSS software (version 20.0). A  $P$  value  $< 0.05$  was considered to indicate statistical significance.

## RESULTS


### *In vivo* study

**Effect of granisetron, ZnPPiX and hemin on the time to first defecation:** The average amount of food eaten before drug administration was 5 g. After 20 min of free access to food, the body weight increased by approximately 8 g in all animals.


Consistent with results obtained in our previous study<sup>[9]</sup>, acute administration of granisetron increased the time to first defecation. Interestingly, the delay to first defecation was dose-dependent, with no significant effect measured for the lowest dose of granisetron used (25  $\mu\text{g/kg}$ ) and with a substantial increase in the time to first defecation observed in animals administered higher doses of granisetron; in this respect, both 50 and 75  $\mu\text{g/kg}$  of granisetron were equally effective (Friedman's test = 13,  $P = 0.005$ , *post hoc*: granisetron 25  $\mu\text{g/kg}$  vs vehicle,  $P = 0.132$ ; granisetron 50  $\mu\text{g/kg}$  vs vehicle,  $P = 0.045$ ; granisetron 75  $\mu\text{g/kg}$  vs vehicle:  $P = 0.045$ ) (Figure 1). A preliminary comparison of the amount of food eaten before vehicle or drug administration showed no statistically significant differences among treatments (Friedman's test = 0.958,  $P = 0.811$ ).

Although ZnPPiX (50  $\mu\text{g/kg}$ ) alone did not modify the time to first defecation, co-administration of ZnPPiX (50  $\mu\text{g/kg}$ ) with granisetron (25, 50, 75  $\mu\text{g/kg}$ ) was able to counteract the constipating effect of granisetron: Friedman's test = 10.486,  $P = 0.033$ ; *post hoc* comparisons: ZnPPiX vs vehicle:  $P = 1$ ; granisetron 25  $\mu\text{g/kg}$  with ZnPPiX vs vehicle:  $P = 1$ ; granisetron 50  $\mu\text{g/kg}$  with ZnPPiX vs vehicle:  $P = 1$ ;






**Figure 1** Effect of *in vivo* administration of granisetron on the time to first defecation. *In vivo* treatment with granisetron (G) significantly increased the time to first defecation at doses of 50 and 75 µg/kg. Friedman's test = 13  $P = 0.005$ , *post hoc*: G 25 µg/kg vs vehicle,  $P = 0.132$ ; G 50 µg/kg vs vehicle,  $^aP = 0.045$ ; G 75 µg/kg vs vehicle,  $^bP = 0.045$ . Each point represents an individual observation.



**Figure 3** Effect of *in vivo* administration of hemin alone and with granisetron on the time to first defecation. Hemin (50 µmol/L/kg) did not affect the time to first defecation. Co-administration of hemin (50 µmol/L/kg) with granisetron (G) (50, 75 µg/kg) resulted in an increased time to first defecation. Friedman's test = 20.364  $P = 0.000$ ; *post-hoc* comparisons: hemin vs vehicle:  $P = 1$ ; G 25 µg/kg + hemin vs vehicle:  $P = 0.108$ ; G 50 µg/kg + hemin vs vehicle:  $^aP = 0.028$ ; G 75 µg/kg + hemin vs vehicle:  $^bP = 0.004$ . Each point represents an individual observation.

granisetron 75 µg/kg with ZnPPiX vs vehicle:  $P = 0.132$  (Figure 2). Similar to the previous case, a preliminary comparison of the amount of food eaten before vehicle or drug administration showed no statistically significant differences among treatments (Friedman's test = 1.077,  $P = 0.898$ ).

On the other hand, hemin (50 µmol/L/kg) alone or co-administered with granisetron (25, 50, 75 µg/kg) showed the following results: Friedman's test = 20.364,  $P = 0.000$ ; *post hoc* comparisons: hemin vs vehicle:  $P = 1.000$ ; granisetron 25 µg/kg with hemin vs vehicle:  $P = 0.108$ ; granisetron 50 µg/kg with hemin vs vehicle:  $P = 0.028$ ; granisetron 75 µg/kg with hemin vs vehicle:  $P = 0.004$ , thus suggesting that hemin does not alter the time to first defecation when administered alone and does not modify the constipating effect of granisetron when administered in combination (Figure 3). Similar to the previous




**Figure 2** Effect of *in vivo* administration of zinc protoporphyrin alone and with granisetron on the time to first defecation. Zinc protoporphyrin (ZnPPiX) (50 µg/kg) did not affect the time to first defecation. Co-administration of ZnPPiX (50 µg/kg) with granisetron (G) (25, 50, 75 µg/kg) abolished the effect of G on its own. Friedman's test = 10.486,  $P = 0.033$ ; *post-hoc* comparisons: ZnPPiX vs vehicle:  $P = 1$ ; G 25 µg/kg + ZnPPiX vs vehicle:  $P = 1$ ; G 50 µg/kg + ZnPPiX vs vehicle:  $P = 1$ ; G 75 µg/kg + ZnPPiX vs vehicle:  $P = 0.132$ . Each point represents an individual observation.

case, a preliminary comparison of the amount of food eaten before vehicle or drug administration showed no statistically significant differences among treatments (Friedman's test = 2.205,  $P = 0.698$ ).

#### *In vitro* studies

**Effects of granisetron on EFS-induced and ACh-induced contractile response of colon preparations:** Incubation of colon specimens with granisetron did not significantly modify the contractile response to EFS obtained in vehicle-treated samples ( $F_{\text{treatments}} = 1.26$ ,  $df = 1/9$ ,  $P = 0.29$ ;  $F_{\text{frequencies}} = 22.50$ ,  $df = 2/18$ ,  $P = 0.001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 1.79$ ,  $df = 2/18$ ,  $P = 0.21$ ) (Figure 4A). Interestingly, a trend to increase the contractile effect induced by ACh (0.1–100 µmol/L) was measured in samples incubated with granisetron, although no statistical significance was measured with respect to vehicle-treated samples ( $F_{\text{treatments}} = 3.48$ ,  $df = 1/9$ ,  $P = 0.09$ ;  $F_{\text{concentrations}} = 21.35$ ,  $df = 3/27$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{concentrations}} = 0.08$ ,  $df = 3/27$ ,  $P = 0.85$ ) (Figure 4B).

**Effects of ZnPPiX on EFS-induced and ACh-induced contractile response of colon preparations:** When compared to vehicle-treated preparations, a significant decrease in the contractile response to EFS was observed in specimens incubated with ZnPPiX (10 µmol/L, 60 min) ( $F_{\text{treatments}} = 8.78$ ,  $df = 1/9$ ,  $P = 0.016$ ;  $F_{\text{frequencies}} = 50.33$ ,  $df = 2/18$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 1.79$ ,  $df = 2/18$ ,  $P = 0.21$ ) (Figure 5A). Interestingly, the ZnPPiX-mediated effect on EFS was abolished by concomitant incubation with atropine (3 µmol/L, 20 min) ( $F_{\text{treatments}} = 1.44$ ,  $df = 1/11$ ,  $P = 0.25$ ;  $F_{\text{frequencies}} = 37.66$ ,  $df = 2/22$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 2.74$ ,  $df = 2/22$ ,  $P = 0.09$ ), therefore suggesting that ZnPPiX may exert its effects by inhibiting the EFS-mediated release of endogenous ACh (Figure 5B). However, ZnPPiX did not affect the contractile



**Figure 4** Effects of *in vitro* treatment with granisetron on rat colon contractile response to electrical field stimulation and to acetylcholine. A: Incubation with granisetron (G) (3  $\mu\text{mol/L}$ , 15 min) did not significantly modify the electrical field stimulation (EFS)-induced contractile response compared to vehicle. ANOVA results:  $F_{\text{treatments}} = 1.26$ ,  $df = 1/9$ ,  $P = 0.29$ ;  $F_{\text{frequencies}} = 22.50$ ,  $df = 2/18$ ,  $P = 0.001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 1.79$ ,  $df = 2/18$ ,  $P = 0.21$ ; B: Incubation with G (3  $\mu\text{mol/L}$ , 15 min) did not affect the contractile response to acetylcholine (ACh) (0.1–100  $\mu\text{mol/L}$ ) compared to vehicle. ANOVA results:  $F_{\text{treatments}} = 3.48$ ,  $df = 1/9$ ,  $P = 0.09$ ;  $F_{\text{concentrations}} = 21.35$ ,  $df = 3/27$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{concentrations}} = 0.08$ ,  $df = 3/27$ ,  $P = 0.85$ . Values are expressed as the mean  $\pm$  SD of 6–8 experiments.

response to exogenous ACh (0.1–100  $\mu\text{mol/L}$ ) compared to vehicle ( $F_{\text{treatments}} = 0.006$ ,  $df = 1/9$ ,  $P = 0.94$ ;  $F_{\text{concentrations}} = 36.89$ ,  $df = 3/27$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{concentrations}} = 0.84$ ,  $df = 3/27$ ,  $P = 0.45$ ) (Figure 5C).

**Effects of CORM-3 on EFS-induced and ACh-induced contractile response of colon preparations:** Assessment of the EFS-induced contractile response after CORM-3 (100–400  $\mu\text{mol/L}$ ) administration shows that CORM-3 (400  $\mu\text{mol/L}$ ) significantly increased the EFS-induced contractile response compared to vehicle at 10 Hz [ $F_{\text{treatments}} = 2.75$ ,  $df = 3/20$ ,  $P = 0.07$ ;  $F_{\text{frequencies}} = 55.38$ ,  $df = 2/40$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 4.36$ ,  $df = 6/40$ ,  $P = 0.002$ ; at 10 Hz: CORM-3 (400  $\mu\text{mol/L}$ ) vs vehicle  $^aP = 0.01$ ] (Figure 6A).

When repeated after 20-min incubation with atropine (3  $\mu\text{mol/L}$ , 20 min), the increased EFS-induced contractile response by CORM-3 (400  $\mu\text{mol/L}$ ) administration was abolished:  $F_{\text{treatments}} = 3.06$ ,  $df = 3/20$ ,  $P = 0.052$ ;  $F_{\text{frequencies}} = 50.05$ ,  $df = 2/40$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 1.14$ ,  $df = 6/40$ ,  $P = 0.36$ . Consistent with the results obtained with ZnPPiX, these observations suggest that CORM-3 may enhance the EFS-induced release of endogenous ACh (Figure 6B).

Analysis performed to determine the effect of CORM-3 administration (100–400  $\mu\text{mol/L}$ ) on the contractile response to exogenous ACh (0.1–100  $\mu\text{mol/L}$ ) showed that incubation with CORM-3 (400  $\mu\text{mol/L}$ ) increases the contractile response to the highest ACh concentration (100  $\mu\text{mol/L}$ ) compared to vehicle-treated samples [ $F_{\text{treatments}} = 2.28$ ,  $df = 3/22$ ,  $P = 0.11$ ;  $F_{\text{concentrations}} = 86.22$ ,  $df = 3/66$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{concentrations}} = 3.49$ ,  $df = 9/66$ ,  $P = 0.02$ ; for ACh 100  $\mu\text{mol/L}$ : CORM-3 (400  $\mu\text{mol/L}$ ) vs vehicle:  $P = 0.012$ ] (Figure 6C).

**Effects of co-administration of granisetron with ZnPPiX or CORM-3 on EFS-induced and ACh-induced contractile response of colon preparations:** When co-administered with granisetron (3


$\mu\text{mol/L}$ , 15 min), incubation with ZnPPiX (10  $\mu\text{mol/L}$ , 60 min) did not significantly modify the EFS-induced contraction compared to vehicle-treated samples ( $F_{\text{treatments}} = 0.43$ ,  $df = 1/8$ ,  $P = 0.53$ ;  $F_{\text{frequencies}} = 55.35$ ,  $df = 2/16$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 1.66$ ,  $df = 2/16$ ,  $P = 0.22$ ) (Figure 7A). Because incubation with ZnPPiX alone decreased the contractile response to EFS (Figure 5A), it is plausible to infer that co-administration of granisetron was responsible for the abolished effects of ZnPPiX on EFS-induced colon contraction.

Co-administration of ZnPPiX (10  $\mu\text{mol/L}$ , 60 min) and granisetron (3  $\mu\text{mol/L}$ , 15 min) did not modify the myogenic contractile response to ACh ( $F_{\text{treatments}} = 0.22$ ,  $df = 1/8$ ,  $P = 0.65$ ;  $F_{\text{concentrations}} = 39.19$ ,  $df = 3/24$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{concentrations}} = 4.06$ ,  $df = 3/24$ ,  $P = 0.02$ ). (Figure 7B).

When the effects of CORM-3 (100–400  $\mu\text{mol/L}$ ) on the EFS-induced contractile response were analyzed in combination with granisetron (3  $\mu\text{mol/L}$ , 15 min), the results showed that co-incubation of CORM-3 (400  $\mu\text{mol/L}$ ) and granisetron significantly increased the EFS-induced contractile response when compared to vehicle-treated samples at 5 and 10 Hz [ $F_{\text{treatments}} = 5.47$ ,  $df = 3/19$ ,  $P < 0.01$ ;  $F_{\text{frequencies}} = 55.40$ ,  $df = 2/38$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 3.05$ ,  $df = 6/38$ ,  $P = 0.04$ ; granisetron (3  $\mu\text{mol/L}$ , 15 min) and CORM-3 (400  $\mu\text{mol/L}$ ) vs vehicle at 5 Hz:  $P = 0.007$  and at 10 Hz:  $P = 0.001$  (Figure 7C).


Interestingly, when compared to vehicle-treated samples, the concomitant incubation of CORM-3 (400  $\mu\text{mol/L}$ ) with granisetron significantly increased the myogenic response to ACh at 10 and 100  $\mu\text{mol/L}$  ( $F_{\text{treatments}} = 7.40$ ,  $df = 3/19$ ,  $P = 0.002$ ;  $F_{\text{concentrations}} = 61.69$ ,  $df = 3/57$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{concentrations}} = 3.55$ ,  $df = 9/57$ ,  $P = 0.027$ ; at ACh 10  $\mu\text{mol/L}$ :  $P = 0.001$  and at ACh 100  $\mu\text{mol/L}$ :  $P = 0.001$ ) (Figure 7D).

**Effects of co-administration of granisetron, ZnPPiX, L-NNA and granisetron, CORM-3, L-NNA on EFS-induced and ACh-induced contractile response of colon preparations:** When co-adminis-




**Figure 5** Effects of *in vitro* treatment with zinc protoporphyrin on rat colon contractile response to electrical field stimulation, without and with atropine, and to acetylcholine. A: Incubation with zinc protoporphyrin (ZnPPiX) (10 μmol/L, 60 min) significantly reduced the electrical field stimulation (EFS)-induced contractile response compared to vehicle. ANOVA results:  $F_{\text{treatments}} = 8.78$ ,  $df = 1/9$ ,  $^aP = 0.016$ ;  $F_{\text{frequencies}} = 50.33$ ,  $df = 2/18$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 1.79$ ,  $df = 2/18$ ,  $P = 0.21$ ; B: Co-incubation with ZnPPiX (10 μmol/L, 60 min) with atropine (3 μmol/L, 20 min) abolished the effect of ZnPPiX alone. ANOVA results:  $F_{\text{treatments}} = 1.44$ ,  $df = 1/11$ ,  $P = 0.25$ ;  $F_{\text{frequencies}} = 37.66$ ,  $df = 2/22$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 2.74$ ,  $df = 2/22$ ,  $P = 0.09$ ; C: Incubation with ZnPPiX (10 μmol/L, 60 min) had no effect on contractile response to atropine (Atr) (0.1–100 μmol/L) compared to vehicle. ANOVA results:  $F_{\text{treatments}} = 0.006$ ,  $df = 1/9$ ,  $P = 0.94$ ;  $F_{\text{concentrations}} = 36.89$ ,  $df = 3/27$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{concentrations}} = 0.84$ ,  $df = 3/27$ ,  $P = 0.45$ . Values are expressed as the mean  $\pm$  SD of 6–8 experiments.

tration of granisetron (3 μmol/L, 15 min) and ZnPPiX (10 μmol/L, 60 min) was combined with L-NNA (100 μmol/L, 20 min), no difference in EFS-induced contractile effects was observed compared to vehicle-treated samples ( $F_{\text{treatments}} = 0.08$ ,  $df = 1/9$ ,  $P = 0.79$ ,  $F_{\text{frequencies}} = 24.89$ ,  $df = 2/18$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{frequencies}}$



**Figure 6** Effects of *in vitro* treatment with CORM-3 on rat colon contractile response to electrical field stimulation, without and with atropine, and to acetylcholine. A: Incubation with CORM-3 (C) (400 μmol/L) significantly increased the electrical field stimulation (EFS)-induced contractile response compared to vehicle at 10 Hz. ANOVA results:  $F_{\text{treatments}} = 2.75$ ,  $df = 3/20$ ,  $P = 0.07$ ;  $F_{\text{frequencies}} = 55.38$ ,  $df = 2/40$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 4.36$ ,  $df = 6/40$ ,  $P = 0.002$ . At 10 Hz: C (400 μmol/L) vs vehicle  $^aP = 0.01$ ; B: Co-incubation of C (100–400 μmol/L) with atropine (Atr) (3 μmol/L, 20 min) abolished the effect of C when administered alone. ANOVA results:  $F_{\text{treatments}} = 3.06$ ,  $df = 3/20$ ,  $P = 0.052$ ;  $F_{\text{frequencies}} = 50.05$ ,  $df = 2/40$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 1.14$ ,  $df = 6/40$ ,  $P = 0.36$ ; C: Incubation with C (400 μmol/L) increased the contractile response to acetylcholine (ACh) (100 μmol/L) compared to vehicle. ANOVA results:  $F_{\text{treatments}} = 2.28$ ,  $df = 3/22$ ,  $P = 0.11$ ;  $F_{\text{concentrations}} = 86.22$ ,  $df = 3/66$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{concentrations}} = 3.49$ ,  $df = 9/66$ ,  $P = 0.02$ . For ACh 100 μmol/L: C (400 μmol/L) vs vehicle:  $^bP = 0.012$ . Values are expressed as the mean  $\pm$  SD of 6–8 experiments.

$= 0.03$ ,  $df = 2/18$ ,  $P = 0.91$ ) (Figure 8A). Similarly, contractile responses to exogenous ACh administration were not modified by concomitant administration of granisetron, ZnPPiX and L-NNA (vs vehicle-treated samples) ( $F_{\text{treatments}} = 0.03$ ,  $df = 1/9$ ,  $P = 0.87$ ;  $F_{\text{concentra-}}$



**Figure 7** Effects of *in vitro* treatment with granisetron and zinc protoporphyrin and with granisetron and CORM-3 on rat colon contractile response to electrical field stimulation (EFS) and to acetylcholine (ACh). A: Co-incubation with granisetron (G) (3 μmol/L, 15 min) and zinc protoporphyrin (ZnPPiX) (10 μmol/L, 60 min) did not significantly modify the EFS-induced contraction compared to vehicle. ANOVA results:  $F_{\text{treatments}} = 0.43$ ,  $df = 1/8$ ,  $P = 0.53$ ;  $F_{\text{frequencies}} = 55.35$ ,  $df = 2/16$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 1.66$ ,  $df = 2/16$ ,  $P = 2$ ; B: Co-incubation with G (3 μmol/L, 15 min) and ZnPPiX (10 μmol/L, 60 min) did not modify the myogenic contractile response to acetylcholine (ACh) (0.1–100 μmol/L) compared to vehicle. ANOVA results:  $F_{\text{treatments}} = 0.22$ ,  $df = 1/8$ ,  $P = 0.65$ ;  $F_{\text{concentrations}} = 39.19$ ,  $df = 3/24$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{concentrations}} = 4.06$ ,  $df = 3/24$ ,  $P = 0.02$ ; C: Co-incubation with G (3 μmol/L, 15 min) and CORM-3 (C) (400 μmol/L) increased the contractile response to EFS at 5 and 10 Hz compared to vehicle. ANOVA results:  $F_{\text{treatments}} = 5.47$ ,  $df = 3/19$ ,  $P < 0.01$ ;  $F_{\text{frequencies}} = 55.40$ ,  $df = 2/38$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 3.05$ ,  $df = 6/38$ ,  $P = 0.04$ . G (3 μmol/L, 15 min) and C (400 μmol/L) vs vehicle at 5 Hz:  $^aP = 0.007$  and at 10 Hz:  $^bP = 0.001$ ; D: Co-incubation of G (3 μmol/L, 15 min) and C (400 μmol/L) increased the contractile response to ACh 10 and 100 μmol/L compared to vehicle. ANOVA results:  $F_{\text{treatments}} = 7.40$ ,  $df = 3/19$ ,  $P = 0.002$ ;  $F_{\text{concentrations}} = 61.69$ ,  $df = 3/57$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{concentrations}} = 3.55$ ,  $df = 9/57$ ,  $P = 0.027$ . G (3 μmol/L, 15 min) and C (400 μmol/L) compared to vehicle at ACh 10 μmol/L:  $^cP = 0.001$  and at ACh 100 μmol/L:  $^dP = 0.001$ . Values are expressed as the mean  $\pm$  SD of 6–8 experiments.

tions = 45.18,  $df = 3/27$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{concentrations}} = 3.90$ ,  $df = 3/27$ ,  $P = 0.04$ ) (Figure 8B).

Co-administration of granisetron (3 μmol/L, 15 min) and CORM-3 (100–400 μmol/L) with L-NNA (100 μmol/L, 20 min) did not affect the EFS-induced contractile response at any frequency investigated (vs vehicle-treated samples) ( $F_{\text{treatments}} = 0.83$ ,  $df = 3/18$ ,  $P = 0.49$ ,  $F_{\text{frequencies}} = 25.51$ ,  $df = 2/36$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 0.89$ ,  $df = 6/36$ ,  $P = 0.50$ ) (Figure 8C) and did not modify the contractile responses to exogenous ACh administration (vs vehicle-treated samples) ( $F_{\text{treatments}} = 3.38$ ,  $df = 3/17$ ,  $P = 0.04$ ;  $F_{\text{concentrations}} = 33.08$ ,  $df = 3/57$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{concentrations}} = 1.47$ ,  $df = 9/51$ ,  $P = 0.25$ , pre-planned contrast not significant) (Figure 8D).

**Effects of co-administration of granisetron and L-NNA on EFS-induced and ACh-induced contractile response of colon preparations:** Co-administration of granisetron (3 μmol/L, 15 min) and L-NNA (100 μmol/L, 20 min) increased the contractile response to EFS compared to vehicle-treated samples ( $F_{\text{treatments}}$


= 6.73,  $df = 1/11$ ,  $P = 0.025$ ;  $F_{\text{frequencies}} = 16.80$ ,  $df = 2/22$ ,  $P = 0.001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 1.26$ ,  $df = 2/22$ ,  $P = 0.30$ ) (Figure 9A).

Likewise, administration of granisetron (3 μmol/L, 15 min) and L-NNA (100 μmol/L, 20 min) increased the myogenic response to ACh compared to vehicle-treated samples ( $F_{\text{treatments}} = 25.33$ ,  $df = 1/11$ ,  $P < 0.001$ ;  $F_{\text{concentrations}} = 80.22$ ,  $df = 3/33$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{concentrations}} = 15.8$ ,  $df = 3/33$ ,  $P = 0.001$ ; *t*-test for ACh 10 μmol/L:  $t = 5.06$ ,  $P = 0.000$  and for ACh 100 μmol/L:  $t = 4.99$ ,  $P = 0.000$ ) (Figure 9B).

## DISCUSSION

This study was planned to clarify the mechanisms underlying the potential contribution of the HO/CO pathway in the constipating effects of granisetron in rats. In a previous report, we found that inhibition of HO or increased expression of HO-1 in rat duodenum was able to influence the granisetron effects on the EFS-dependent response<sup>[9]</sup>. These findings provided a first evidence that the HO/CO pathway may play a






**Figure 8** Effects of *in vitro* treatment with granisetron, zinc protoporphyrin and N<sup>6</sup>-nitro-L-Arginine and with granisetron, CORM-3 and L-NNA on rat colon contractile response to electrical field stimulation and to acetylcholine. A: Co-incubation with granisetron (G) (3 μmol/L, 15 min), ZnPPiX (10 μmol/L, 60 min) and N<sup>6</sup>-nitro-L-Arginine (L-NNA) (100 μmol/L, 20 min) did not affect the electrical field stimulation (EFS)-induced contractile response compared to vehicle. ANOVA results:  $F_{\text{treatments}} = 0.08$ ,  $df = 1/9$ ,  $P = 0.79$ ;  $F_{\text{frequencies}} = 24.89$ ,  $df = 2/18$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 0.03$ ,  $df = 2/18$ ,  $P = 0.91$ ; B: Co-incubation with G (3 μmol/L, 15 min), zinc protoporphyrin (ZnPPiX) (10 μmol/L, 60 min) and L-NNA (100 μmol/L, 20 min) did not affect the contractile response to acetylcholine (ACh) (0.1–100 μmol/L) compared to vehicle. ANOVA results:  $F_{\text{treatments}} = 0.03$ ,  $df = 1/9$ ,  $P = 0.87$ ;  $F_{\text{concentrations}} = 45.18$ ,  $df = 3/27$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{concentrations}} = 3.90$ ,  $df = 3/27$ ,  $P = 0.04$ ; C: Co-incubation with G (3 μmol/L, 15 min), C (100–400 μmol/L) and L-NNA (100 μmol/L, 20 min) did not affect the EFS-induced contractile response compared to vehicle. ANOVA results:  $F_{\text{treatments}} = 0.83$ ,  $df = 3/18$ ,  $P = 0.49$ ,  $F_{\text{frequencies}} = 25.51$ ,  $df = 2/36$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 0.89$ ,  $df = 6/36$ ,  $P = 0.50$ ; D: Co-incubation with G (3 μmol/L, 15 min), CORM-3 (C) (100–400 μmol/L) and L-NNA (100 μmol/L, 20 min) did not affect the contractile response to ACh (0.1–100 μmol/L) compared to vehicle. ANOVA results:  $F_{\text{treatments}} = 3.38$ ,  $df = 3/17$ ,  $P = 0.04$ ,  $F_{\text{concentrations}} = 33.08$ ,  $df = 3/57$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{concentrations}} = 1.47$ ,  $df = 9/51$ ,  $P = 0.25$ . Values are expressed as the mean  $\pm$  SD of 6–8 experiments.

role in the constipating activity of granisetron. However, because constipation is more closely related to abnormalities of colon motility, rather than in the duodenum<sup>[16–19]</sup>, we planned to focus directly on the colon contractile responses. Moreover, in our previous study, the role of the HO/CO pathway on rat duodenum was evaluated under NANC conditions<sup>[9]</sup> to avoid the overwhelming effects of the main neurotransmitters at the gastrointestinal level, namely ACh and noradrenaline (NA). However, neurogenic gastrointestinal motility is strictly dependent on ACh and NA-mediated effects, and the functional relevance of NANC neurotransmission *in vivo* is still largely unknown<sup>[30]</sup>. Thus, in this work, the assessment of colon neurogenic response to granisetron was investigated under conditions directly resembling the existing intestinal environment.

Consistent with literature data reporting constipation in patients treated with granisetron as an antiemetic therapy<sup>[11,15]</sup>, we observed an increased time to first defecation, a recognized indicator of whole-gut transit<sup>[24,25]</sup>, after acute administration of granisetron in rats. Granisetron-induced constipation was abol-

ished by *in vivo* co-administration with ZnPPiX (HO inhibitor), whereas co-administration of hemin (HO-1 inducer) did not decrease the delayed time to first defecation observed in granisetron-treated rats. These data support an active role of the HO/CO system in the constipating effect of granisetron<sup>[9]</sup>. Interestingly, neither ZnPPiX nor hemin was able to affect rat gastrointestinal motility when administered alone *in vivo*. This is not surprising because the HO/CO pathway is likely to be a fine-tuning mechanism whose activity may enhance or limit the extension of major signals involved in the integrated control of colon motility.

Consistent with this view, and with studies reporting a substantial effect of 5-HT<sub>3</sub> antagonists only in the presence of high levels of 5-HT, either exogenously administered or endogenously released from enterochromaffin cells (for example, by mucosal pressure, distortion and/or chemical stimuli<sup>[31–33]</sup>), granisetron administration *in vitro* did not significantly inhibit the contractile response to EFS and showed a borderline trend to increase the contraction mediated by ACh ( $P = 0.09$ ). Interestingly, colon contractile responses to



**Figure 9** Effects of *in vitro* treatment with granisetron and  $N^6$ -nitro-L-Arginine on rat colon contractile response to electrical field stimulation and to acetylcholine. **A:** Co-incubation with granisetron (G) ( $3 \mu\text{mol/L}$ , 15 min) and  $N^6$ -nitro-L-Arginine (L-NNA) ( $100 \mu\text{mol/L}$ , 20 min) resulted in significantly increase of electrical field stimulation (EFS)-induced contractile responses at all frequencies used compared to vehicle. ANOVA results:  $F_{\text{treatments}} = 6.73$ ,  $df = 1/11$ ,  $^aP = 0.025$ ;  $F_{\text{frequencies}} = 16.80$ ,  $df = 2/22$ ,  $P = 0.001$ ;  $F_{\text{treatments} \times \text{frequencies}} = 1.26$ ,  $df = 2/22$ ,  $P = 0.30$ ; **B:** Co-incubation with G ( $3 \mu\text{mol/L}$ , 15 min) and L-NNA ( $100 \mu\text{mol/L}$ , 20 min) resulted in significantly increased contractile response induced by acetylcholine (ACh) (10 and  $100 \mu\text{mol/L}$ ) compared to vehicle. ANOVA results:  $F_{\text{treatments}} = 25.33$ ,  $df = 1/11$ ,  $P < 0.001$ ;  $F_{\text{concentrations}} = 80.22$ ,  $df = 3/33$ ,  $P < 0.0001$ ;  $F_{\text{treatments} \times \text{concentrations}} = 15.8$ ,  $df = 3/33$ ,  $P = 0.001$ . *T*-test for ACh  $10 \mu\text{mol/L}$ :  $t = 5.06$ ,  $^bP = 0.000$  and for ACh  $100 \mu\text{mol/L}$ :  $t = 4.99$ ,  $^cP = 0.000$ . Values are expressed as the mean  $\pm$  SD of 6-8 experiments.

EFS were decreased *in vitro* by incubation with ZnPIX alone. Because ZnPIX inhibits the HO-mediated production of CO, it is plausible to infer that the EFS-dependent contraction is mediated, at least in part, by CO. This hypothesis is consistent with studies reporting an almost completely abolished inhibitory response to EFS in jejunal smooth muscle strips of mice with targeted genomic deletion of HO-2. Concomitantly, in these animals, an exogenous administration of CO restores the EFS response<sup>[34]</sup>.


CO appears to have a facilitatory effect on EFS-mediated ACh release, as suggested by the impaired ACh release observed in frog neuromuscular junctions under ZnPIX incubation<sup>[35]</sup>. Analogous behavior was observed in our study in which the impaired contractile response to EFS obtained under ZnPIX was restored by concomitant incubation with the muscarinic antagonist atropine. This finding, together with the lack of any effect of ZnPIX on the myogenic contractile response to exogenous ACh, implies that a phasic CO production is required for physiological ACh release in rat colon.

The potential role of CO on granisetron effects, investigated *in vivo* by co-administration of hemin, was mimicked *in vitro* by co-administration of CORM-3, a CO-releasing molecule able to replicate the effects of HO-1 stimulation with hemin<sup>[3,36]</sup>. At the highest dose used ( $400 \mu\text{mol/L}$ ) CORM-3 significantly increases the contractile response to both EFS (10 Hz) and exogenous ACh ( $100 \mu\text{mol/L}$ ). These findings suggest that one mechanism by which CO may enhance the contractile response in rat colon is by facilitating the release of endogenous ACh. In addition, CO may indirectly potentiate the ACh contractile effects, as proposed by Lim *et al*<sup>[37]</sup>, by concurrently activating L-type calcium channels in human intestinal smooth muscle *via* a nitric oxide (NO)-dependent mechanism. The binding of NO to guanylyl cyclase with subsequent changes in cAMP and intracellular  $\text{Ca}^{2+}$  levels will eventually lead to activation of the "contractile apparatus"<sup>[37]</sup>.

When granisetron and CORM-3 were co-administered, the colon's contractile responses to both EFS and ACh were further increased, suggesting a synergistic effect between these two substances. Similarly, when granisetron and ZnPIX were co-administered, the effects of ZnPIX alone were lost. Although the exact mechanism of granisetron and HO/CO system interplay remains to be clearly established, some explanations may be proposed: one is that, as suggested by the bell-shaped curve for *in vivo* response<sup>[38]</sup>, granisetron may behave as a partial agonist at the concentrations used for the present *in vitro* and *in vivo* studies<sup>[39,40]</sup>. In this case, the activation of 5-HT<sub>3</sub> receptors followed by subsequent increased release of ACh may have overcome the inhibition of ACh release secondary to ZnPIX. Concomitantly, acting as a partial 5-HT<sub>3</sub> agonist, granisetron may synergistically potentiate CORM-3 effects by increasing calcium influx.

Because the activation of L-type  $\text{Ca}^{2+}$  channels operated by CO is a NO-dependent mechanism, inhibition of NO production is expected to decrease the CORM-3-mediated effects. Indeed, in the presence of NO synthase inhibitor L-NNA, the potentiating effect of CORM-3 on granisetron activity was lost, confirming the necessary role of NO for the observed activities.

Because of the nature of the study, the following limitations must be considered. First, we cannot conclusively exclude that the colon response to granisetron/ZnPIX treatment might be related to changes in the serotonergic system; nevertheless, the results obtained strongly suggest that the constipating effect of granisetron is only indirectly affected by ZnPIX, which acts through reduction of EFS-induced acetylcholine release. Second, it is not clear whether the alleviation of granisetron-induced constipation might affect the antiemetic potential of this drug; studies directly evaluating this parameter would require a specific animal model and a completely different experimental approach, both of which are unavailable at this time. However, our per-



**Figure 10** Potential relationship between granisetron, ZnPPiX (HO-1/2 inhibitor), and CORM-3 (CO-releasing agent) on colon neurogenic and myogenic contractile responses. Acting on 5-HT<sub>3</sub> receptors, granisetron may increase calcium influx, thus facilitating the release of acetylcholine (ACh) (neurogenic response), which in turn elicits a myogenic contractile response. By inhibiting the heme oxygenase (HO)-mediated carbon monoxide (CO) production, ZnPPiX may reduce the nerve terminal release of ACh, thereby counteracting granisetron effects. By releasing carbon monoxide (CO), CORM-3 may enhance the ACh-mediated myogenic contraction via a nitric oxide (NO)-dependent mechanism resulting in increased intracellular cAMP and calcium levels, with subsequent activation of L-type calcium channels and potentiation of the granisetron-mediated myogenic response.

ception is that alleviation of granisetron-induced constipation does not interfere with its antiemetic activity because this last effect relates to granisetron's ability to reach the CNS. In this regard, it has been reported that ZnPPiX does not cross the blood-brain barrier<sup>[1,41]</sup>. Thus, it is plausible that the effects of ZnPPiX to reduce granisetron-induced constipation are related to peripheral mechanisms not involving the CTZ. Third, gastrointestinal transit (GIT) was measured by observing the time to first defecation after food ingestion; although intragastric administration of a non-absorbable, colored marker is considered the reference method to measure GIT, additional gavage administration would increase stress in animals and potentially affect the parameter evaluated. In our study, we considered the delayed GIT in rats treated with granisetron (compared to rats treated with vehicle) as a positive control to evaluate the effects of ZnPPiX and CORM-3 on the "time to first defecation" after food ingestion.

In conclusion, findings from the present study may shed light on the involvement of the HO/CO pathway in the neurogenic and myogenic contractile responses in rat colon and propose potential mechanisms underlying the interaction of granisetron and CO on colon motility (Figure 10).

Considering that granisetron is mainly used to pre-

vent chemotherapy-induced nausea and vomiting in cancer patients and that increased expression of HO-1 has been observed in several cancer types<sup>[42]</sup>, our findings suggest that HO inhibitors may be a reasonable therapeutic approach to reduce the unwanted constipating effects of granisetron.

## ACKNOWLEDGEMENTS

The authors would like to thank Mr. Domenico Gallo and Dr. Anna De Salvia for their technical support.

## COMMENTS

### Background

In recent decades, the role played by carbon monoxide (CO) in several biochemical processes has been increasingly recognized. Once considered only for its lethal effects, the therapeutic use of CO has been proposed after the discovery of its potential "positive" functions. Ion channels have been shown to be, among others, the target of CO; thus, it is possible that CO may modulate the effects of other signals by acting directly on the same target or indirectly on the shared pool of secondary messengers. A similar modulating activity of CO might also be plausible toward specific drugs.

### Research frontiers

In a previous report, authors observed the involvement of the heme oxygenase (HO)/CO pathway in granisetron-mediated effects on duodenal motility.

## Innovations and breakthroughs

Findings from the present study may shed light on the involvement of the HO/CO pathway in the neurogenic and myogenic contractile responses in rat colon and propose potential mechanisms underlying the interaction of granisetron and CO on colon motility.

## Applications

Considering that granisetron is mainly used to prevent chemotherapy-induced nausea and vomiting in cancer patients and that increased expression of HO-1 has been observed in several cancer types<sup>[42]</sup>, the authors findings suggest that HO inhibitors may be a reasonable therapeutic approach to reduce the unwanted constipating effects of granisetron.

## Terminology

Electrical field stimulation allows measurement of the neurogenic contractile response. In rat colon preparations, the electrical field stimulation (EFS) induces an immediate relaxation of specimens followed, at the end of EFS, by a contraction called off-contraction. This contractile response is indicative of a nervous reflex. Moreover, activation of enteric nerves by electrical field stimulation mimics the *in vivo* conditions because neurotransmitters are released by motor neurons to the neuroeffector apparatus in which interstitial cells of Cajal, neurons, glial cells and smooth muscle cells interact and induce contraction.

## Peer-review

The authors present interesting data about HO/CO pathway and granisetron. The authors report detailed data and proposed potential mechanisms underlying the interaction of granisetron and CO. Overall, it is an important study, and should be considered for publication.

## REFERENCES

- 1 Wu L, Wang R. Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. *Pharmacol Rev* 2005; **57**: 585-630 [PMID: 16382109]
- 2 Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. *Physiol Rev* 2006; **86**: 583-650 [PMID: 16601269 DOI: 10.1152/physrev.00011.2005]
- 3 Gibbons SJ, Verhulst PJ, Bharucha A, Farrugia G. Review article: carbon monoxide in gastrointestinal physiology and its potential in therapeutics. *Aliment Pharmacol Ther* 2013; **38**: 689-702 [PMID: 23992228 DOI: 10.1111/apt.12467]
- 4 Zakhary R, Poss KD, Jaffrey SR, Ferris CD, Tonegawa S, Snyder SH. Targeted gene deletion of heme oxygenase 2 reveals neural role for carbon monoxide. *Proc Natl Acad Sci USA* 1997; **94**: 14848-14853 [PMID: 9405702]
- 5 Farrugia G, Szurszewski JH. Carbon monoxide, hydrogen sulfide, and nitric oxide as signaling molecules in the gastrointestinal tract. *Gastroenterology* 2014; **147**: 303-313 [PMID: 24798417 DOI: 10.1053/j.gastro.2014.04.041]
- 6 Peers C. Modulation of ion channels and transporters by carbon monoxide: causes for concern? *Front Physiol* 2012; **3**: 477 [PMID: 23267333 DOI: 10.3389/fphys.2012.00477]
- 7 Wilkinson WJ, Kemp PJ. Carbon monoxide: an emerging regulator of ion channels. *J Physiol* 2011; **589**: 3055-3062 [PMID: 21521759 DOI: 10.1113/jphysiol.2011.206706]
- 8 Peers C, Boyle JP, Scragg JL, Dallas ML, Al-Owais MM, Hettiarachichi NT, Elies J, Johnson E, Gamper N, Steele DS. Diverse mechanisms underlying the regulation of ion channels by carbon monoxide. *Br J Pharmacol* 2015; **172**: 1546-1556 [PMID: 24818840 DOI: 10.1111/bph.12760]
- 9 Zigrino A, Leo V, Renna G, Montagnani M, De Salvia MA. Hemin and Zinc Protoporphyrin IX Affect Granisetron Constipating Effects In Vitro and In Vivo. *ISRN Gastroenterol* 2013; **2013**: 612037 [PMID: 23864955 DOI: 10.1155/2013/612037]
- 10 Derkach V, Surprenant A, North RA. 5-HT<sub>3</sub> receptors are membrane ion channels. *Nature* 1989; **339**: 706-709 [PMID: 2472553 DOI: 10.1038/339706a0]
- 11 Aapro M. 5-HT<sub>3</sub>-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. *Oncology* 2005; **69**: 97-109 [PMID: 16131816 DOI: 10.1159/000087979]
- 12 Navari RM, Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. *N Engl J Med* 2016; **374**: 1356-1367 [PMID: 27050207 DOI: 10.1056/NEJMra1515442]
- 13 Chetty N, Irving HR, Coupar IM. Activation of 5-HT<sub>3</sub> receptors in the rat and mouse intestinal tract: a comparative study. *Br J Pharmacol* 2006; **148**: 1012-1021 [PMID: 16770318 DOI: 10.1038/sj.bjp.0706802]
- 14 Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. *Lancet* 2000; **355**: 1035-1040 [PMID: 10744088 DOI: 10.1016/S0140-6736(00)02033-X]
- 15 Beattie DT, Smith JA. Serotonin pharmacology in the gastrointestinal tract: a review. *Naunyn Schmiedeberg's Arch Pharmacol* 2008; **377**: 181-203 [PMID: 18398601 DOI: 10.1007/s00210-008-0276-9]
- 16 Koch KL, Bitar KN, Fortunato JE. Tissue engineering for neuromuscular disorders of the gastrointestinal tract. *World J Gastroenterol* 2012; **18**: 6918-6925 [PMID: 23322989 DOI: 10.3748/wjg.v18.i47.6918]
- 17 Bassotti G, Imbimbo BP, Betti C, Dozzini G, Morelli A. Impaired colonic motor response to eating in patients with slow-transit constipation. *Am J Gastroenterol* 1992; **87**: 504-508 [PMID: 1553939]
- 18 Bazzocchi G, Ellis J, Villanueva-Meyer J, Jing J, Reddy SN, Mena I, Snape WJ. Postprandial colonic transit and motor activity in chronic constipation. *Gastroenterology* 1990; **98**: 686-693 [PMID: 2404826 DOI: 10.1016/0016-5085(90)90289-D]
- 19 Wiskur B, Greenwood-Van Meerveld B. The aging colon: the role of enteric neurodegeneration in constipation. *Curr Gastroenterol Rep* 2010; **12**: 507-512 [PMID: 20878508 DOI: 10.1007/s11894-010-0139-7]
- 20 Poli E, Lazzaretti M, Grandi D, Pozzoli C, Coruzzi G. Morphological and functional alterations of the myenteric plexus in rats with TNBS-induced colitis. *Neurochem Res* 2001; **26**: 1085-1093 [PMID: 11699935]
- 21 Fornai M, Pellegrini C, Antonioli L, Segnani C, Ippolito C, Barocelli E, Ballabeni V, Vegezzi G, Al Harraq Z, Blandini F, Levandis G, Cerri S, Blandizzi C, Bernardini N, Colucci R. Enteric Dysfunctions in Experimental Parkinson's Disease: Alterations of Excitatory Cholinergic Neurotransmission Regulating Colonic Motility in Rats. *J Pharmacol Exp Ther* 2016; **356**: 434-444 [PMID: 26582732 DOI: 10.1124/jpet.115.228510]
- 22 Motterlini R, Gonzales A, Foresti R, Clark JE, Green CJ, Winslow RM. Heme oxygenase-1-derived carbon monoxide contributes to the suppression of acute hypertensive responses in vivo. *Circ Res* 1998; **83**: 568-577 [PMID: 9734480 DOI: 10.1161/01.RES.83.5.568]
- 23 Gan HT, Chen JD. Induction of heme oxygenase-1 improves impaired intestinal transit after burn injury. *Surgery* 2007; **141**: 385-393 [PMID: 17349851 DOI: 10.1016/j.surg.2006.06.023]
- 24 Marona HR, Lucchesi MB. Protocol to refine intestinal motility test in mice. *Lab Anim* 2004; **38**: 257-260 [PMID: 15207036 DOI: 10.3201/eid0905.020428]
- 25 Bove GM. A non-invasive method to evaluate gastrointestinal transit behavior in rat. *J Pharmacol Toxicol Methods* 2015; **74**: 1-6 [PMID: 25913851]
- 26 Mitolo-Chieppa D, Mansi G, Nacci C, De Salvia MA, Montagnani M, Potenza MA, Rinaldi R, Lerro G, Siro-Brigiani G, Mitolo CI, Rinaldi M, Altomare DF, Memeo V. Idiopathic chronic constipation: tachykinins as cotransmitters in colonic contraction. *Eur J Clin Invest* 2001; **31**: 349-355 [PMID: 11298783]
- 27 Martín-Cano FE, Camello PJ, Pozo MJ. Characterization of the motor inhibitory role of colonic mucosa under chemical stimulation in mice. *Am J Physiol Gastrointest Liver Physiol* 2014; **306**: G614-G621 [PMID: 24525019 DOI: 10.1152/ajpgi.00208.2013]
- 28 Sanders KM, Hwang SJ, Ward SM. Neuroeffector apparatus in gastrointestinal smooth muscle organs. *J Physiol* 2010; **588**: 4621-4639 [PMID: 20921202 DOI: 10.1113/jphysiol.2010.196030]
- 29 McLean S, Begg R, Jesse HE, Mann BE, Sanguinetti G, Poole RK. Analysis of the bacterial response to Ru(CO)<sub>3</sub>Cl(Glycinate)



- (CORM-3) and the inactivated compound identifies the role played by the ruthenium compound and reveals sulfur-containing species as a major target of CORM-3 action. *Antioxid Redox Signal* 2013; **19**: 1999-2012 [PMID: 23472713 DOI: 10.1089/ars.2012.5103]
- 30 **Lecci A**, Capriati A, Altamura M, Maggi CA. Tachykinins and tachykinin receptors in the gut, with special reference to NK2 receptors in human. *Auton Neurosci* 2006; **126-127**: 232-249 [PMID: 16616700 DOI: 10.1016/j.autneu.2006.02.014]
  - 31 **Bertrand PP**, Hu X, Mach J, Bertrand RL. Serotonin (5-HT) release and uptake measured by real-time electrochemical techniques in the rat ileum. *Am J Physiol Gastrointest Liver Physiol* 2008; **295**: G1228-G1236 [PMID: 18927211 DOI: 10.1152/ajpgi.90375.2008]
  - 32 **Smith TK**, Gershon MD. CrossTalk proposal: 5-HT is necessary for peristalsis. *J Physiol* 2015; **593**: 3225-3227 [PMID: 26228547 DOI: 10.1113/JP270182]
  - 33 **Spencer NJ**, Sia TC, Brookes SJ, Costa M, Keating DJ. CrossTalk opposing view: 5-HT is not necessary for peristalsis. *J Physiol* 2015; **593**: 3229-3231 [PMID: 26228548 DOI: 10.1113/JP270183]
  - 34 **Xue L**, Farrugia G, Miller SM, Ferris CD, Snyder SH, Szurszewski JH. Carbon monoxide and nitric oxide as coneurotransmitters in the enteric nervous system: evidence from genomic deletion of biosynthetic enzymes. *Proc Natl Acad Sci USA* 2000; **97**: 1851-1855 [PMID: 10677545]
  - 35 **Sitdikova GF**, Islamov RR, Mukhamedyarov MA, Permyakova VV, Zefirov AL, Palotás A. Modulation of neurotransmitter release by carbon monoxide at the frog neuro-muscular junction. *Curr Drug Metab* 2007; **8**: 177-184 [PMID: 17305496]
  - 36 **Wang G**, Hamid T, Keith RJ, Zhou G, Partridge CR, Xiang X, Kingery JR, Lewis RK, Li Q, Rokosh DG, Ford R, Spinale FG, Riggs DW, Srivastava S, Bhatnagar A, Bolli R, Prabhu SD. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. *Circulation* 2010; **121**: 1912-1925 [PMID: 20404253 DOI: 10.1161/CIRCULATIONAHA.109.905471]
  - 37 **Lim I**, Gibbons SJ, Lyford GL, Miller SM, Strega PR, Sarr MG, Chatterjee S, Szurszewski JH, Shah VH, Farrugia G. Carbon monoxide activates human intestinal smooth muscle L-type Ca<sup>2+</sup> channels through a nitric oxide-dependent mechanism. *Am J Physiol Gastrointest Liver Physiol* 2005; **288**: G7-14 [PMID: 15319183 DOI: 10.1152/ajpgi.00205.2004]
  - 38 **Darmani NA**, Chebolu S, Amos B, Alkam T. Synergistic antiemetic interactions between serotonergic 5-HT<sub>3</sub> and tachykininergic NK1-receptor antagonists in the least shrew (*Cryptotis parva*). *Pharmacol Biochem Behav* 2011; **99**: 573-579 [PMID: 21683089 DOI: 10.1016/j.pbb.2011.05.025]
  - 39 **Mourad FH**, O'Donnell LJ, Dias JA, Ogutu E, Andre EA, Turvill JL, Farthing MJ. Role of 5-hydroxytryptamine type 3 receptors in rat intestinal fluid and electrolyte secretion induced by cholera and *Escherichia coli* enterotoxins. *Gut* 1995; **37**: 340-345 [PMID: 7590428]
  - 40 **Schulzke JD**, Pfaffenbach S, Fromm A, Epple HJ, Troeger H, Fromm M. Prostaglandin I(2) sensory input into the enteric nervous system during distension-induced colonic chloride secretion in rat colon. *Acta Physiol (Oxf)* 2010; **199**: 305-316 [PMID: 20136796 DOI: 10.1111/j.1748-1716.2010.02096.x]
  - 41 **Li X**, Clark JD. The role of heme oxygenase in neuropathic and incisional pain. *Anesth Analg* 2000; **90**: 677-682 [PMID: 10702456 DOI: 10.1097/0000539-200003000-00031]
  - 42 **Fest S**, Soldati R, Christiansen NM, Zenclussen ML, Kilz J, Berger E, Starke S, Lode HN, Engel C, Zenclussen AC, Christiansen H. Targeting of heme oxygenase-1 as a novel immune regulator of neuroblastoma. *Int J Cancer* 2016; **138**: 2030-2042 [PMID: 26595750 DOI: 10.1002/ijc.29933]

**P- Reviewer:** Garcia-Olmo D, Sacharczuk M, Takano S

**S- Editor:** Yu J **L- Editor:** A **E- Editor:** Wang CH





Published by **Baishideng Publishing Group Inc**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>



ISSN 1007-9327

